chr17-44372391-CA-C

Variant summary

Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM4PP4_StrongPM2_SupportingPM3_Supporting

This summary comes from the ClinGen Evidence Repository: The NM_000419.5(ITGA2B):c.3092del (p.Leu1031ArgfsTer?) variant causes a frameshift and subsequent stop loss. This results in the addition of 90 amino acids to the ITGA2B protein, beyond the cytoplasmic domain (PM4). The variant is absent from gnomAD v2.1.1 (PM2_Supporting). At least one patient (Patient GT11 in PMID:25373348) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia. Additionally, αIIbβ3 surface expression was reduced between 5% and 20% and function was pathological, as measured by flow cytometry (PP4_strong). This patient is compound heterozygous for the maternal c.3092del variant and Leu214Pro (classified Pathogenic by the PD-EP), without confirmation of trans phase (PM3_supporting). In summary this variant meets criteria to be classified as Likely Pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PP4_strong, PM2_supporting, PM3_supporting, PM4. (VCEP specifications version 2; date of approval xx/xx/xxxx) LINK:https://erepo.genome.network/evrepo/ui/classification/CA915940323/MONDO:0100326/011

Frequency

Genomes: not found (cov: 31)
Exomes 𝑓: 0.0000014 ( 0 hom. )

Consequence

ITGA2B
NM_000419.5 frameshift

Scores

Not classified

Clinical Significance

Likely pathogenic reviewed by expert panel P:2

Conservation

PhyloP100: 2.94
Variant links:
Genes affected
ITGA2B (HGNC:6138): (integrin subunit alpha 2b) This gene encodes a member of the integrin alpha chain family of proteins. The encoded preproprotein is proteolytically processed to generate light and heavy chains that associate through disulfide linkages to form a subunit of the alpha-IIb/beta-3 integrin cell adhesion receptor. This receptor plays a crucial role in the blood coagulation system, by mediating platelet aggregation. Mutations in this gene are associated with platelet-type bleeding disorders, which are characterized by a failure of platelet aggregation, including Glanzmann thrombasthenia. [provided by RefSeq, Jan 2016]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 8 ACMG points.

PM2
PM3
PM4
PP4

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
ITGA2BNM_000419.5 linkuse as main transcriptc.3092del p.Leu1031ArgfsTer? frameshift_variant 30/30 ENST00000262407.6
ITGA2BXM_011524749.2 linkuse as main transcriptc.3143del p.Leu1048ArgfsTer? frameshift_variant 29/29
ITGA2BXM_011524750.2 linkuse as main transcriptc.3128del p.Leu1043ArgfsTer? frameshift_variant 29/29

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
ITGA2BENST00000262407.6 linkuse as main transcriptc.3092del p.Leu1031ArgfsTer? frameshift_variant 30/301 NM_000419.5 P1P08514-1
ITGA2BENST00000648408.1 linkuse as main transcriptc.2406del p.Leu803ArgfsTer? frameshift_variant 25/25
ITGA2BENST00000587295.5 linkuse as main transcriptc.285del p.Leu96ArgfsTer? frameshift_variant 3/33

Frequencies

GnomAD3 genomes
Cov.:
31
GnomAD4 exome
AF:
0.00000137
AC:
2
AN:
1461872
Hom.:
0
Cov.:
30
AF XY:
0.00000275
AC XY:
2
AN XY:
727244
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000232
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
Cov.:
31

ClinVar

Significance: Likely pathogenic
Submissions summary: Pathogenic:2
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Glanzmann thrombasthenia Pathogenic:1
Likely pathogenic, reviewed by expert panelcurationClinGen Platelet Disorders Variant Curation Expert Panel, ClinGenDec 02, 2021The NM_000419.5(ITGA2B):c.3092del (p.Leu1031ArgfsTer?) variant causes a frameshift and subsequent stop loss. This results in the addition of 90 amino acids to the ITGA2B protein, beyond the cytoplasmic domain (PM4). The variant is absent from gnomAD v2.1.1 (PM2_Supporting). At least one patient (Patient GT11 in PMID:25373348) with this variant displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia. Additionally, alphaIIbbeta3 surface expression was reduced between 5% and 20% and function was pathological, as measured by flow cytometry (PP4_strong). This patient is compound heterozygous for the maternal c.3092del variant and Leu214Pro (classified Pathogenic by the PD-EP), without confirmation of trans phase (PM3_supporting). In summary this variant meets criteria to be classified as Likely Pathogenic for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PP4_strong, PM2_supporting, PM3_supporting, PM4. (VCEP specifications version 2; date of approval xx/xx/xxxx) -
Glanzmann thrombasthenia 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpMar 19, 2024Variant summary: ITGA2B c.3092delT (p.Leu1031ArgfsX70+) causes a frameshift which results in an extension of the protein. This variant results in the addition of 90 amino acids to the ITGA2B protein, beyond the cytoplasmic domain. The variant was absent in 251356 control chromosomes. c.3092delT has been reported in the literature in at-least two individuals affected with Glanzmann thrombasthenia, in each case, it was at a compound heterozygous along with a different pathogenic missense (example, Sandrock-Lang_2015, Sharma_2021). These data indicate that the variant may be associated with disease. Additionally, a similar extension variant c.3091delC variant causes a frameshift Leu1031TrpfsTer97 and subsequent stop loss, also adds 90 amino acids to the ITGA2B protein, and was evaluated Likely Pathogenic per ClinGen Platelet Disorders Variant Curation Expert Panel (ClinVar ID 1879040). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 25373348, 34267460). ClinVar contains an entry for this variant (Variation ID: 1691488). Based on the evidence outlined above, the variant was classified as likely pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

No publications associated with this variant yet.

Other links and lift over

hg19: chr17-42449759; API